1. Societal cost of cancer in Norway –Results of taking a broader cost perspective
- Author
-
Ivar Sønbø Kristiansen, Christoffer Bugge, Odd Terje Brustugun, and Erik Magnus Sæther
- Subjects
Indirect costs ,Quality of life (healthcare) ,Cost of Illness ,Environmental health ,Neoplasms ,Health care ,medicine ,Production (economics) ,Humans ,Societal cost ,Activity-based costing ,health care economics and organizations ,Cancer ,Cervical cancer ,Production loss ,business.industry ,Norway ,Health Policy ,Health Care Costs ,medicine.disease ,Years of potential life lost ,Absenteeism ,Quality of Life ,Cost of illness ,business ,Years of life lost - Abstract
Background The broader cost consequences of diseases may be of interest for a wide range of stakeholders. We aimed to estimate all relevant societal costs of cancer and to provide insight into the relative magnitude of the different cost categories. Method We used data from eight different health and work-related registries in Norway. Direct, indirect, and intangible costs (value of lost life years) were estimated over a period of one year with a combination of a top-down and a bottom-up costing approach. Results The indirect costs (EUR 1,997 million per year) are almost as high as direct costs (EUR 2,154 million), and the value of lost life years and quality of life represents the greatest cost related to cancer (EUR 18,200 million). In addition, cancer is associated with other costs which are commonly omitted from cost-of-illness analyses, including informal nursing (EUR 306 million), patient time costs (EUR 85 million), and excess costs of using public funds (EUR 439 million). Breast and cervical cancer had relatively high work absenteeism costs, while pancreatic and lung cancer had relatively high production costs due to premature deaths. Discussion Direct health care costs represent small proportions of the total societal costs of cancer. Costs commonly omitted in cost-of-illness analyses represent a significant cost and should be measured and valued in these analyses.
- Published
- 2021